Armata Pharmaceuticals, Inc. Stock

Equities

ARMP

US04216R1023

Biotechnology & Medical Research

Market Closed - Nyse 04:10:00 2025-02-14 pm EST 5-day change 1st Jan Change
1.950 USD -2.01% Intraday chart for Armata Pharmaceuticals, Inc. -6.25% +5.41%

Valuation: Armata Pharmaceuticals, Inc.

Capitalization 70.56M 67.28M 63.42M 56.07M 99.99M 6.11B 111M 755M 280M 2.55B 264M 259M 10.74B P/E ratio 2024 *
-2.05x
P/E ratio 2025 * -1.15x
Enterprise value 70.56M 67.28M 63.42M 56.07M 99.99M 6.11B 111M 755M 280M 2.55B 264M 259M 10.74B EV / Sales 2024 *
12.8x
EV / Sales 2025 * 12.8x
Free-Float
-
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
Armata Pharmaceuticals, Inc. Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection Dec. 19 CI
Armata Pharmaceuticals, Inc. Concludes Employment Agreement with Mina Pastagia as Chief Medical Officer Dec. 04 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 13 CI
Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia Nov. 12 CI
Armata Pharmaceuticals Announces Principal Financial Officer Changes 24-08-15 CI
Armata Pharmaceuticals, Inc. Announces Appointment of David House as SVP of Finance, Effective August 16 24-08-15 CI
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 24-07-30 CI
Armata Pharmaceuticals, Inc. Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled Ap-Pa02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas Aeruginosa Infection 24-07-11 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 24-05-07 CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 24-05-07 MT
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M 24-03-21 MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-21 CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 24-03-21 CI
More news
1 day-2.01%
1 week-6.25%
Current month-2.50%
1 month-2.66%
3 months-19.09%
6 months-20.08%
Current year+5.41%
More quotes
1 week
1.85
Extreme 1.85
2.22
1 month
1.85
Extreme 1.85
2.37
Current year
1.85
Extreme 1.85
2.37
1 year
1.80
Extreme 1.8
4.48
3 years
0.83
Extreme 0.8311
5.79
5 years
0.83
Extreme 0.8311
10.48
10 years
0.83
Extreme 0.8311
10.48
More quotes
Director TitleAgeSince
Chief Executive Officer 69 2023-07-10
Director of Finance/CFO 41 2024-08-15
Chief Operating Officer - -
Manager TitleAgeSince
Director/Board Member 61 2019-05-08
Director/Board Member 67 2019-10-09
Director/Board Member 65 2020-02-11
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-2.01%-6.25%-39.44%-62.21% 70.56M
-0.77%-2.20%+7.67%+96.65% 118B
-0.10%-5.13%-29.45%+6.90% 72.09B
-2.13%-3.83%+68.23%+140.90% 38.79B
-2.40%+1.89%+28.97%-26.68% 28.73B
+2.38%+3.29%+58.05%+4.99% 24.63B
+4.61%+2.25%+11.97%-36.61% 23.61B
-2.06%+6.27%+357.60%+957.92% 15.76B
+0.81%-0.80%+175.86%+226.51% 14.19B
+0.94%+8.59%-19.89%-31.61% 13.46B
Average -0.07%+0.33%+61.96%+127.68% 34.92B
Weighted average by Cap. -0.26%-1.16%+33.89%+96.58%
See all sector performances

Financials

2024 *2025 *
Net sales 5.5M 5.24M 4.94M 4.37M 7.79M 476M 8.66M 58.87M 21.8M 199M 20.61M 20.2M 837M 5.5M 5.24M 4.94M 4.37M 7.79M 476M 8.66M 58.87M 21.8M 199M 20.61M 20.2M 837M
Net income -34.8M -33.18M -31.28M -27.65M -49.32M -3.01B -54.81M -372M -138M -1.26B -130M -128M -5.3B -68.6M -65.41M -61.67M -54.51M -97.22M -5.94B -108M -734M -272M -2.48B -257M -252M -10.45B
Net Debt - -
More financial data * Estimated data
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Employees
66
More about the company
Date Price Change Volume
25-02-14 1.950 $ -2.01% 7,429
25-02-13 1.990 $ +2.05% 13,540
25-02-12 1.950 $ -2.01% 3,808
25-02-11 1.990 $ -1.49% 15,315
25-02-10 2.020 $ -2.88% 4,263

Delayed Quote Nyse, February 14, 2025 at 04:10 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.950USD
Average target price
7.000USD
Spread / Average Target
+258.97%
Consensus

Quarterly revenue - Rate of surprise